BEIGENE LTD-ADR (ONC) Stock News
NASDAQ:ONC - Nasdaq - US07725L1026 - ADR - Currency: USD
ONC Latest News, Press Relases and Analysis
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference
BeiGene Stock Meets 80-Plus RS Rating Benchmark
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday.
Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics
The headline numbers for BeiGene (ONC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
Community Health Q1 Earnings Top on Rising Patient Volumes, Stock Up 8%
CYH continues to witness growth in same-store admissions in the first quarter. Net loss per share is expected between 55 cents and breakeven in 2025.
Universal Health Q1 Earnings Beat on Strong Acute Care Admissions
UHS continues to witness growth in acute care facilities' patient days, while behavioral health care services witness decline.
Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial
The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.
BeiGene to Announce First Quarter 2025 Financial Results on May 7
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz
/PRNewswire/ -- Equity Insider News Commentary – Routine medical appointments or cancer screenings—critical for catching the disease in earlier, more treatable...
Mentions: ONCY
Reddit initiated, Roku upgraded: Wall Street's top analyst calls
Reddit initiated, Roku upgraded: Wall Street's top analyst calls
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
BeiGene to Present at Upcoming Investor Conferences
BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism
The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for certain patients with advanced or metastatic non-small cell lung cancer
Mentions: IBRX